Fluoxymesterone halotesin CAS 76-43-7 with high purity

Product Details

Fluoxymesterone (halotesin)

Name:Androst-4-en-3-one,9-fluoro-11,17-dihydroxy-17-methyl-, (11b,17b)-

Superlist Name:Fluoxymesterone

Density:1.22 g/cm3

Melting Point:240 degrees Celsius

Boiling Point:474.2 degrees Celsius at 760 mmHg

Flash Point:240.6 degrees Celsius

Solubility:water: ≤0.5 mg/mL

Adverse effects

In clinical trials, the most common adverse effects of Fluoxymesterone halotesin use included headache, flushing, indigestion, nasal congestion, and impaired vision, including photophobia and blurred vision. Some Fluoxymesterone halotesin users have complained of seeing everything tinted blue (cyanopsia).Some complained of blurriness and loss of peripheral vision. In July 2005, the FDA found that Fluoxymesterone halotesin could lead to vision impairment in rare cases and a number of studies have linked Fluoxymesterone halotesin use with non-arteritic anterior ischemic optic neuropathy.^[14] Rare but serious adverse effects found through postmarketing surveillance include prolonged erections, severe low blood pressure,myocardial infarction (heart attack), ventricular arrhythmias, stroke, increased intraocular pressure, and sudden hearing loss.^[2] In October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including Fluoxymesterone halotesin, required a more prominent warning of the potential risk of sudden hearing loss.